Entrada Therapeutics is a biotechnology company. Co. is focused on the development of Endosomal Escape Vehicle (EEV) therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1. In its neuromuscular disease programs, Co. links EEVs to small strands of nucleic acids called oligonucleotides, including phosphorodiamidate morpholino oligomers (PMOs). Co. is developing EEV-PMOs that promote the skipping of these mutations associated with DMD. Co.'s therapeutic candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. The TRDA YTD return is shown above.
The YTD Return on the TRDA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TRDA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TRDA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|